The reverse split authorization is a binary catalyst — if approved, the board can act within 12 months to regain Nasdaq compliance, but the massive warrant overhang (~29.9M shares vs 15.4M outstanding) means any post-split price stability is uncertain. Monitor the December 3 vote outcome and subsequent board decision on split ratio and timing.
Price Chart
Executive Summary
Traws Pharma is holding a special meeting on December 3, 2026 to seek stockholder approval for a reverse stock split (1-for-8 to 1-for-15) to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a deficiency notice on July 29, 2026. The filing is a routine governance proxy with no executive compensation, director election, or shareholder proposal details — the sole material item is the reverse split authorization needed to avoid delisting.
Key Facts
- Stock price closed at $0.59 on September 30, 2026, well below the $1.00 minimum bid price requirement
- Nasdaq deficiency notice received July 29, 2026; 180-day compliance period ends January 25, 2027
- Board seeks authority to implement reverse split at ratio between 1-for-8 and 1-for-15 within 12 months of approval
- 15,368,277 common shares outstanding as of October 6, 2026 record date
- 29,914,595 shares reserved for outstanding warrants — massive overhang relative to current float
- Top institutional holders include OrbiMed (11.70%), Sirenia Capital (9.99%), Ikarian (9.45%), Ally Bridge (7.59%), Perceptive (5.99%)
- If split not approved, common stock could be delisted from Nasdaq
- Fractional shares will be rounded up to nearest whole share; no cash in lieu
Financial Impact
Reverse split at 1-for-15 would reduce outstanding shares from ~15.4M to ~1.0M; at 1-for-8 to ~1.9M. No change to authorized shares (250M common), creating proportional increase in authorized-but-unissued shares available for future dilutive issuance.
Risk Factors
- Stockholders may not approve the reverse split, leading to Nasdaq delisting
- Post-split price may decline back to pre-split levels as seen in many historical reverse splits
- Massive warrant overhang (~29.9M shares) will continue to pressure post-split price
- Increased authorized-but-unissued shares create future dilution risk
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001104659-26-117406 |
| Document: 0001104659-26-117406-index-headers.html | 0001104659-26-117406 |
| Document: 0001104659-26-117406-index.html | 0001104659-26-117406 |
| Document: 0001104659-26-117406.txt | 0001104659-26-117406 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $0.3500 | awaiting T+20 | — | $0.3400 (+2.86%) |
Oct 23, 2026 3d ago | 8-K | $0.3510 | awaiting T+20 | — | $0.3400 (+3.13%) |
Oct 20, 2026 6d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3400 (−9.57%) |
Oct 20, 2026 6d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3400 (+9.57%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3400 (+37.04%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3400 (+55.26%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3400 (−55.26%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3400 (−55.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers